Brixton Biosciences

Brixton Biosciences is a clinical-stage life sciences company that develops novel therapies for treating pain. Backed by deep research, the company addresses crucial unmet needs in pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide pain relief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution.

Brixton Biosciences headquartered in United States, North America, operates in the Information Technology, Biotechnology, Life Science sector. The company focuses on Information Technology and has secured $792.0M in funding across 24 round(s). With a team of 1-10 employees, Brixton Biosciences is actively contributing to advancements in Information Technology. Their latest funding round, Series B - Brixton Biosciences, raised $33.0M. Discover more about their projects, partnerships, and impact on our platform.